Literature DB >> 23409736

Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure.

Merce Gasa1, Renaud Tamisier, Sandrine H Launois, Marc Sapene, Francis Martin, Bruno Stach, Yves Grillet, Patrick Levy, Jean-Louis Pepin.   

Abstract

Hypoxic brain damage might explain persistent sleepiness in some continuous positive airway pressure-compliant obstructive sleep apnea called residual excessive sleepiness. Although continuous positive airway pressure may not be fully efficient in treating this symptom, wake-promoting drug prescription in residual excessive sleepiness is no longer allowed by the European Medicines Agency. The aim of this study is to describe residual excessive sleepiness phenotypes in a large prospective sample of patients with obstructive sleep apnea. Residual excessive sleepiness was defined by an Epworth Sleepiness Scale score ≥ 11. Eligible patients from the French National Sleep Registry attending follow-up continuous positive airway pressure visits numbered 1047. Patients using continuous positive airway pressure < 3 h (n = 275), with residual apnea-hypopnea index > 15 h⁻¹ (n = 31) or with major depression were excluded (n = 150). Residual excessive sleepiness prevalence in continuous positive airway pressure-treated obstructive sleep apnea was 13% (18% for those with an initial Epworth Sleepiness Scale score > 11), and significantly decreased with continuous positive airway pressure use (9% in ≥ 6 h night⁻¹ continuous positive airway pressure users, P < 0.005). At the time of diagnosis, patients with residual excessive sleepiness had worse subjective appreciation of their disease (general health scale, Epworth Sleepiness Scale and fatigue score), and complained more frequently of continuous positive airway pressure side-effects. Residual excessive sleepiness prevalence was lower in severe obstructive sleep apnea than in moderate obstructive sleep apnea (11% when AHI > 30 h⁻¹ versus 18% when AHI 15-30, P < 0.005). There was no relationship between residual excessive sleepiness and body mass index, cardiovascular co-morbidities or diabetes. Continuous positive airway pressure improved symptoms in the whole population, but to a lower extent in patients with residual excessive sleepiness (fatigue scale: -5.2 versus -2.7 in residual excessive sleepiness- and residual excessive sleepiness+ patients, respectively, P < 0.001). Residual excessive sleepiness prevalence decreased with continuous positive airway pressure compliance. Hypoxic insult is unlikely to explain residual excessive sleepiness as obstructive sleep apnea severity does not seem to be critical. Residual symptoms are not limited to sleepiness, suggesting a true 'continuous positive airway pressure-resistant syndrome', which may justify treatment by wake-promoting drugs.
© 2013 European Sleep Research Society.

Entities:  

Keywords:  continuous positive airway pressure; depression; residual excessive sleepiness; sleep apnea

Mesh:

Year:  2013        PMID: 23409736     DOI: 10.1111/jsr.12039

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  29 in total

1.  Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis.

Authors:  Shashvat Sukhal; Madiha Khalid; Aiman Tulaimat
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

2.  Comorbidities, Health-Related Quality of Life, and Work Productivity Among People With Obstructive Sleep Apnea With Excessive Sleepiness: Findings From the 2016 US National Health and Wellness Survey.

Authors:  Carl Stepnowsky; Kathleen F Sarmiento; Shay Bujanover; Kathleen F Villa; Vicky W Li; Natalia M Flores
Journal:  J Clin Sleep Med       Date:  2019-02-15       Impact factor: 4.062

3.  Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.

Authors:  Paula K Schweitzer; Russell Rosenberg; Gary K Zammit; Mark Gotfried; Dan Chen; Lawrence P Carter; Hao Wang; Yuan Lu; Jed Black; Atul Malhotra; Kingman P Strohl
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

4.  Effect of CPAP Therapy in Improving Daytime Sleepiness in Indian Patients with Moderate and Severe OSA.

Authors:  Gulshan Battan; Sanjeev Kumar; Ajay Panwar; Virendra Atam; Pradeep Kumar; Anil Gangwar; Ujjawal Roy
Journal:  J Clin Diagn Res       Date:  2016-11-01

5.  White matter structural differences in OSA patients experiencing residual daytime sleepiness with high CPAP use: a non-Gaussian diffusion MRI study.

Authors:  Jiaxuan Zhang; Terri E Weaver; Zheng Zhong; Robyn A Nisi; Kelly R Martin; Alana D Steffen; M Muge Karaman; Xiaohong Joe Zhou
Journal:  Sleep Med       Date:  2018-09-29       Impact factor: 3.492

Review 6.  Contemporary Concise Review 2019: Sleep and ventilation.

Authors:  Bernie Y Sunwoo; Christopher N Schmickl; Atul Malhotra
Journal:  Respirology       Date:  2020-02-11       Impact factor: 6.424

Review 7.  Hypersomnia.

Authors:  Pradeep C Bollu; Sivaraman Manjamalai; Mahesh Thakkar; Pradeep Sahota
Journal:  Mo Med       Date:  2018 Jan-Feb

8.  Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.

Authors:  Russell Rosenberg; Michelle Baladi; Morgan Bron
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

9.  Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.

Authors:  Russell Rosenberg; Michael J Thorpy; Yves Dauvilliers; Paula K Schweitzer; Gary Zammit; Mark Gotfried; Shay Bujanover; Brian Scheckner; Atul Malhotra
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

10.  Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.

Authors:  Paula K Schweitzer; Kingman P Strohl; Geert Mayer; Russell Rosenberg; Patricia Chandler; Michelle Baladi; Lawrence Lee; Atul Malhotra
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.